ClinicalTrials.gg
CompletedNCT04930562Updated Jan 17, 2024Results posted

Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

A Phase 2 interventional study of BN101 in GVHD, Chronic, sponsored by BioNova Pharmaceuticals (Shanghai) LTD.. Completed at 7 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-17.

Sponsored by BioNova Pharmaceuticals (Shanghai) LTD. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome — 7 open to participants now, 8 under way, 2 of them phase 3. belumosudil · Bronchiolitis Obliterans Syndrome.

Enrollment
8th of 14
30 · median 34
Started
2021
the only one that year
Phase 2
8 of 14
3 open now
Registered
2nd of 14
by date
Lead sponsor
1 of 14
BioNova Pharmaceuticals (Shanghai) LTD.

Among the 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome, this one is the 8th largest by enrollment, is the only one that started in 2021, is one of 8 in phase 2, and was the 2nd registered.

Bronchiolitis Obliterans Syndrome

714 studies on the registry are indexed under Bronchiolitis Obliterans Syndrome; 128 are open to participants now.

Browse Bronchiolitis Obliterans Syndrome studies →

Open to participants now

7 of the 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About belumosudil

belumosudil: first FDA approval 2021 (REZUROCK), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 100 Bronchiolitis Obliterans Syndrome studies recruiting now, 45 (45%) set no upper age limit and 45 (45%) stop at 75 or younger; 25 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing belumosudil in Bronchiolitis Obliterans Syndrome, or all of them as a file.
02

Study summary

This is a phase 2, open-label, multicenter trial to evaluate the efficacy and safety of BN101 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least First Line of systemic therapy.

Read the detailed description

Approximately 30 subjects will be enrolled to receive orally administered BN101 200 mg QD (once daily)

Study drug will be administered in 28-day cycles until disease progression or unacceptable toxicity. Subjects may receive study drug in the inpatient or outpatient setting.

Curative Effect analysis The efficacy was analyzed based on MITT The point estimate and 95%CI of ORR were calculated based on the exact probability method of binomial distribution.If applicable, a logistic regression model will be used for multivariate analysis.

Descriptive statistical analyses were provided for all secondary efficacy endpoints.

The following subgroups will be analysed:

  • Severe cGVHD (Yes/No)
  • Number of organs involved (\<4 vs. ≥4)
  • Number of previous systemic cGVHD treatment (1 vs. ≥2)
  • Duration of cGVHD before inclusion (i.e., from the time of cGVHD diagnosis to the time of inclusion)
  • Lung Involvement (Yes/No)
03

Conditions studied

  • GVHD, Chronic
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects at least 18 years of age who have had allogenic hematopoietic cell transplant (HCT).
  • Previously received at least 1 and not more than 5 for cGVHD
  • Receiving therapy with a stable dose over the 2 weeks prior to screening;
  • Have persistent cGVHD manifestations and systemic therapy is indicated

Exclusion criteria

Exclusion Criteria:

  • Subject has not been on a stable dose / regimen of systemic cGVHD treatments for at least 2 weeks prior to screening. (Note: Concomitant , calcineurin inhibitors, sirolimus, MMF, methotrexate, rituximab, and extracorporeal photophoresis (ECP) are acceptable. Systemic treatments are not permitted).
  • Histological relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.
  • Current treatment with ibrutinib. Prior treatment with ibrutinib is allowed with a of at least 28 days prior to treatment.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    200mg qd

    200mg qd po.

    Drug: BN101

Interventions

  • DrugBN101

    BN101 is an orally ROCK2 selective inhibitor

    Also known as: belumosudil, KD025

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    OR was defined as the percentage of participants with complete response (CR) or partial response (PR). The OR determination of chronic graft versus host disease (cGVHD) was based on cGVHD response assessment performed by clinicians as per the 2014 National Institutes of Health (NIH) Consensus Development Project for Clinical Trials in cGVHD criteria. CR was defined as the resolution of all manifestations in each organ or site. PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; and cGVHD progression was defined as the clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.

    Time frame: 12 Months

Secondary outcomes

  1. Duration of Response (DOR)

    The DOR was defined as the time (in weeks) from first documentation of response to the time of first documentation of deterioration from best response (e.g., CR to PR, or PR to LR). LOR included the response status of unchanged (LOR-U), mixed (LOR-M), or progression (LOR-P). Per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; LOR-M was defined as CR or PR in at least one organ accompanied by progression in another organ, LOR-U was defined as outcomes that did not meet the criteria for CR, PR, progression or mixed response, LOR-P was defined as progression in at least one organ or site without a response in any other organ or site. Kaplan-Meier was used for the analysis.

    Time frame: 12 Months

  2. Time-to-Response (TTR)

    Time-to-response was measured as the time (in weeks) from first dose of study drug to the time of first documentation of response. Response was defined as the participants achieving a PR or CR at any post-baseline response assessment. Per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site and PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site

    Time frame: 12 months

  3. Number of Participants With Best Response in Each Individual Organ

    Best response was defined as the percentage of participants with CR or PR. Response was assessed per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site. Organ response assessment was performed on 9 individual organs: skin, eyes, mouth, esophagus, upper gastrointestinal (GI), lower GI, liver, lungs, and joints and fascia and is reported in this outcome measure.

    Time frame: 12 months

  4. Number of Participants With Change From Baseline in Overall Score on Lee cGvHD Symptom Scale at Specified Time Points

    Lee cGVHD symptom scale, a patient-reported symptom scale used to measure symptom burden and has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0-Not at all, 1-Slightly, 2-Moderately, 3-Quite a bit, 4-Extremely, with lower values representing better outcome. Score for each subscale was normalized to a score ranged from 0 to 100, where higher score=worse symptoms. An overall Lee cGvHD score was calculated as average of these 7 subscales and it ranged from 0 to 100, where a higher score = worse symptoms. EOT visit was performed within 3 days after the participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication.

    Time frame: Baseline and 12 months

  5. Failure-free Survival (FFS)

    Failure-free survival was defined as the time (in months) from first dose of study drug to either the start of another new systemic treatment for cGVHD, relapse of the underlying disease or death. If no such events happened, FFS was censored by last response assessment or long term follow up assessment, whichever was the latest and available. Kaplan-Meier survival method was used for the analysis.

    Time frame: 12 months

  6. Time to Next Therapy (TTNT)

    The TTNT was defined as the time (in months) from first treatment to the time of new systemic cGVHD treatment. TTNT was censored by last response assessment or long term follow up assessment, whichever was earlier. Kaplan-Meier survival method was used for the analysis.

    Time frame: 12months

  7. Overall Survival (OS)

    Overall survival was defined as the time (in months) from first dose of study drug to the death due to any reason. If there was no death, OS was censored by last visit, last long-term follow-up, or study cut-off date, whichever occurred first. Kaplan-Meier survival method was used for the analysis.

    Time frame: 12months

  8. Change From Baseline in Corticosteroids Dose

    Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 7 days after the participant's last dose of study drug.

    Time frame: 12months

  9. Number of Participants With Change From Baseline in Calcineurin Inhibitor (CNI) Usage.

    Calcineurin inhibitors included systemic tacrolimus and cyclosporine. Number of participants who took CNI at Baseline and had reduction and discontinuation in CNI use as compared to Baseline during the study are reported in this outcome measure. EOT visit was performed within 7 days after the participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication.

    Time frame: 12months

  10. Change From Baseline in in Global Severity Rating (GSR) Score by Clinician-reported cGVHD Assessment

    The GSR assessment was performed by asking the participants to rate their disease severity of cGVHD symptoms on a 0 to 10-point numeric rating scale, where score 0 indicated 'not at all severe cGVHD symptoms' and score 10 indicated 'most severe cGVHD symptoms possible'. The response was defined using scores from 9 organs: skin, eyes, mouth, esophagus, upper gastrointestinal (GI) track, lower GI tract, liver, lungs, and joints and fascia plus GSR. End of treatment (EOT) visit was performed within 7 days after participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. Change from Baseline was calculated as GSR score at Baseline minus the lowest GSR score on scheduled visits with possible ranges from -10 to 10. The higher the number means the better improvement in cGVHD symptoms. Only those categories in which at least 1 participant had data were reported.

    Time frame: 12months

  11. Change From Baseline in Symptom Activity by cGVHD Activity Assessment Participant Self-Report

    cGVHD symptom severity was self-reported by participants. Participants were asked to rate their disease symptom severity over the last week on the following questions: skin itching at its worst, moth dryness at its worst, mouth pain at its worst, mouth sensitivity at its worst, main compliant on eyes, symptom severity on eyes. Severity rating was done on a 0 to 10-point numeric rating scare, where score 0 indicated 'not at all severe cGVHD symptoms' and score 10 indicated 'most severe cGVHD symptoms possible'. EOT visit was performed within 7 days after participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. Change from Baseline was calculated as the symptom severity score at Baseline minus the lowest symptom severity score on scheduled visits minuswith possible ranges from -10 to 10. The higher the number means the better improvement in cGVHD symptoms.

    Time frame: 12months

07

Results

Posted Nov 1, 2023

Participant flow

Participant flow — Overall Study
Milestone200mg qd
Started30
Completed30
Not completed0

Outcome measures

PrimaryOverall Response Rate (ORR)

OR was defined as the percentage of participants with complete response (CR) or partial response (PR). The OR determination of chronic graft versus host disease (cGVHD) was based on cGVHD response assessment performed by clinicians as per the 2014 National Institutes of Health (NIH) Consensus Development Project for Clinical Trials in cGVHD criteria. CR was defined as the resolution of all manifestations in each organ or site. PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; and cGVHD progression was defined as the clinically meaningful worsening in 1 or more organs regardless of improvement in other organs.

Time frame:
12 Months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participants200mg qd
Overall Response Rate (ORR)73.3 (54.1 to 87.7)
SecondaryDuration of Response (DOR)

The DOR was defined as the time (in weeks) from first documentation of response to the time of first documentation of deterioration from best response (e.g., CR to PR, or PR to LR). LOR included the response status of unchanged (LOR-U), mixed (LOR-M), or progression (LOR-P). Per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site; LOR-M was defined as CR or PR in at least one organ accompanied by progression in another organ, LOR-U was defined as outcomes that did not meet the criteria for CR, PR, progression or mixed response, LOR-P was defined as progression in at least one organ or site without a response in any other organ or site. Kaplan-Meier was used for the analysis.

Time frame:
12 Months
Reported as:
Median · weeks
Duration of Response (DOR)
weeks200mg qd
Duration of Response (DOR)20.2 (9.71 to NA)
SecondaryTime-to-Response (TTR)

Time-to-response was measured as the time (in weeks) from first dose of study drug to the time of first documentation of response. Response was defined as the participants achieving a PR or CR at any post-baseline response assessment. Per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site and PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site

Time frame:
12 months
Reported as:
Median · weeks
Time-to-Response (TTR)
weeks200mg qd
Time-to-Response (TTR)4.29 (3.9 to 48.1)
SecondaryNumber of Participants With Best Response in Each Individual Organ

Best response was defined as the percentage of participants with CR or PR. Response was assessed per the 2014 NIH Consensus Development Project for Clinical Trials in cGVHD criteria; CR was defined as the resolution of all manifestations in each organ or site; PR was defined as the improvement in at least 1 organ or site without progression in any other organ or site. Organ response assessment was performed on 9 individual organs: skin, eyes, mouth, esophagus, upper gastrointestinal (GI), lower GI, liver, lungs, and joints and fascia and is reported in this outcome measure.

Time frame:
12 months
Reported as:
Number · participants
Number of Participants With Best Response in Each Individual Organ
participants200mg qd
Skin8
Eyes6
Mouth12
Esophagus3
Upper GI tract2
Liver6
Lungs2
Joints and Fascia7
SecondaryNumber of Participants With Change From Baseline in Overall Score on Lee cGvHD Symptom Scale at Specified Time Points

Lee cGVHD symptom scale, a patient-reported symptom scale used to measure symptom burden and has 7 subscales (Skin, Eyes and Mouth, Breathing, Eating and Digestion, Muscles and Joints, Energy, and Mental and Emotional) with ratings as follows: 0-Not at all, 1-Slightly, 2-Moderately, 3-Quite a bit, 4-Extremely, with lower values representing better outcome. Score for each subscale was normalized to a score ranged from 0 to 100, where higher score=worse symptoms. An overall Lee cGvHD score was calculated as average of these 7 subscales and it ranged from 0 to 100, where a higher score = worse symptoms. EOT visit was performed within 3 days after the participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication.

Time frame:
Baseline and 12 months
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Overall Score on Lee cGvHD Symptom Scale at Specified Time Points
Participants200mg qd
Total score decline of 7 or more points from baseline15
Total score declined by 7 or more points from baseline on two consecutive assessments10
SecondaryFailure-free Survival (FFS)

Failure-free survival was defined as the time (in months) from first dose of study drug to either the start of another new systemic treatment for cGVHD, relapse of the underlying disease or death. If no such events happened, FFS was censored by last response assessment or long term follow up assessment, whichever was the latest and available. Kaplan-Meier survival method was used for the analysis.

Time frame:
12 months
Reported as:
Median · months
Failure-free Survival (FFS)
months200mg qd
Failure-free Survival (FFS)NA (7.79 to NA)
SecondaryTime to Next Therapy (TTNT)

The TTNT was defined as the time (in months) from first treatment to the time of new systemic cGVHD treatment. TTNT was censored by last response assessment or long term follow up assessment, whichever was earlier. Kaplan-Meier survival method was used for the analysis.

Time frame:
12months
Reported as:
Median · months
Time to Next Therapy (TTNT)
months200mg qd
Time to Next Therapy (TTNT)NA (8.9 to NA)
SecondaryOverall Survival (OS)

Overall survival was defined as the time (in months) from first dose of study drug to the death due to any reason. If there was no death, OS was censored by last visit, last long-term follow-up, or study cut-off date, whichever occurred first. Kaplan-Meier survival method was used for the analysis.

Time frame:
12months
Reported as:
Median · months
Overall Survival (OS)
months200mg qd
Overall Survival (OS)NA (NA to NA)
SecondaryChange From Baseline in Corticosteroids Dose

Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. EOT visit was performed within 7 days after the participant's last dose of study drug.

Time frame:
12months
Reported as:
Mean · milligrams per kilogram per day
Change From Baseline in Corticosteroids Dose
milligrams per kilogram per day200mg qd
Change From Baseline in Corticosteroids Dose0.277 ± 0.202
SecondaryNumber of Participants With Change From Baseline in Calcineurin Inhibitor (CNI) Usage.

Calcineurin inhibitors included systemic tacrolimus and cyclosporine. Number of participants who took CNI at Baseline and had reduction and discontinuation in CNI use as compared to Baseline during the study are reported in this outcome measure. EOT visit was performed within 7 days after the participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication.

Time frame:
12months
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline in Calcineurin Inhibitor (CNI) Usage.
Participants200mg qd
Participants with reduction in CNI dose7
Participants who discontinued CNI3
SecondaryChange From Baseline in in Global Severity Rating (GSR) Score by Clinician-reported cGVHD Assessment

The GSR assessment was performed by asking the participants to rate their disease severity of cGVHD symptoms on a 0 to 10-point numeric rating scale, where score 0 indicated 'not at all severe cGVHD symptoms' and score 10 indicated 'most severe cGVHD symptoms possible'. The response was defined using scores from 9 organs: skin, eyes, mouth, esophagus, upper gastrointestinal (GI) track, lower GI tract, liver, lungs, and joints and fascia plus GSR. End of treatment (EOT) visit was performed within 7 days after participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. Change from Baseline was calculated as GSR score at Baseline minus the lowest GSR score on scheduled visits with possible ranges from -10 to 10. The higher the number means the better improvement in cGVHD symptoms. Only those categories in which at least 1 participant had data were reported.

Time frame:
12months
Reported as:
Mean · score
Change From Baseline in in Global Severity Rating (GSR) Score by Clinician-reported cGVHD Assessment
score200mg qd
Change From Baseline in in Global Severity Rating (GSR) Score by Clinician-reported cGVHD Assessment5.4 ± 1.99
SecondaryChange From Baseline in Symptom Activity by cGVHD Activity Assessment Participant Self-Report

cGVHD symptom severity was self-reported by participants. Participants were asked to rate their disease symptom severity over the last week on the following questions: skin itching at its worst, moth dryness at its worst, mouth pain at its worst, mouth sensitivity at its worst, main compliant on eyes, symptom severity on eyes. Severity rating was done on a 0 to 10-point numeric rating scare, where score 0 indicated 'not at all severe cGVHD symptoms' and score 10 indicated 'most severe cGVHD symptoms possible'. EOT visit was performed within 7 days after participant's last dose of study drug. Baseline value was defined as valid and last non-missing value obtained within 28 days prior to participant receiving first study medication. Change from Baseline was calculated as the symptom severity score at Baseline minus the lowest symptom severity score on scheduled visits minuswith possible ranges from -10 to 10. The higher the number means the better improvement in cGVHD symptoms.

Time frame:
12months
Reported as:
Mean · score
Change From Baseline in Symptom Activity by cGVHD Activity Assessment Participant Self-Report
score200mg qd
Change From Baseline in Symptom Activity by cGVHD Activity Assessment Participant Self-Report2.8 ± 3.07

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
200mg qd5/30 (16.7%)11/30 (36.7%)29/30 (96.7%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
Event200mg qd
PneumoniaInfections and infestations5/30
Upper respiratory tract infectionInfections and infestations1/30
Neutrophil count decreasedInvestigations1/30
Oral infectionsInfections and infestations1/30
Mouth ulcerationGastrointestinal disorders1/30
MyocarditisCardiac disorders1/30
White blood cell count decreasedInvestigations1/30
Leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30
Skin bacterial infectionInfections and infestations1/30
Pneumonia bacterialInfections and infestations1/30
Most frequent other events
Showing 10 of 35
Most frequent other events
Event200mg qd
Upper respiratory tract infectionInfections and infestations12/30
Sinus tachycardiaCardiac disorders11/30
PneumoniaInfections and infestations7/30
HyperuricaemiaMetabolism and nutrition disorders5/30
Liver injuryHepatobiliary disorders5/30
HypertensionBlood and lymphatic system disorders3/30
Alanine aminotransferase increasedInvestigations3/30
Blood creatinine increasedInvestigations3/30
Blood glucose increasedInvestigations3/30
NauseaGastrointestinal disorders3/30

Baseline characteristics

Age, Continuous
Age, Continuous(years)200mg qd
Mean30.6 ± 9.28
Sex: Female, Male
Sex: Female, Male(Participants)200mg qd
Female9
Male21
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)200mg qd
Han29
Other1
BMI
BMI(kg/m^2)200mg qd
Mean19.78 ± 3.459
08

Study locations

7 sites
  • Peking University People's Hospital
    Beijing, China
  • Xinqiao Hospital, Army Medical University
    Chongqing, China
  • Guangzhou First People's Hospital
    Guangzhou, China
  • Nanfang Hospital
    Guangzhou, China
  • Zhujiang Hospital of Southern Medical University
    Guangzhou, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, 215006, China
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2021 to primary completion in Jun 2022, 13 months.

Results were first posted in Nov 2023, 1 year 4 months after primary completion.

Of 63 phase 2 interventional studies under Bronchiolitis Obliterans Syndrome, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2021
First posted
Jun 18, 2021
StartActual
Apr 27, 2021
Primary completionActual
Jun 10, 2022
CompletionActual
Dec 10, 2022
Results first posted
Nov 1, 2023
Last update
Jan 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04930562
Lead sponsor
BioNova Pharmaceuticals (Shanghai) LTD.
Responsible party
Sponsor
First posted
Jun 18, 2021
Start date
Apr 27, 2021
Primary completion
Jun 10, 2022
Completion
Dec 10, 2022
Results posted
Nov 1, 2023
Last update
Jan 17, 2024

Study contacts

Depei Wu, Prof
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belumosudil

Start the discussion